A general assessment of the safety of HMG CoA reductase inhibitors (statins).

被引：50

作者：

Black D.M. ^{[1
]}

机构：

[1] Medical Research Laboratories International, Highland Heights, 2 Tesseneer Avenue, 41076, KY

来源：

Current Atherosclerosis Reports | 2002年 / 4卷 / 1期

关键词：

Statin; Simvastatin; Atorvastatin; Myopathy; Pravastatin;

D O I：

10.1007/s11883-002-0060-0

中图分类号：

学科分类号：

摘要：

Few principles in medicine today are as well accepted as the benefits of using statins to reduce cardiovascular risk factors and to prevent cardiovascular disease. The recent withdrawal of a statin (cerivastatin) has lead to a re-examination of all statins, and an attempt to better assess the risk-benefit ratio of this class of drugs. Although the benefits of statin treatment are well known from a myriad of clinical trials, the safety of these compounds has not been an issue since lovastatin was first introduced in 1987. This report provides a brief review of statin safety, and reiterates the excellent profile of this class of drugs.

引用

页码：34 / 41

页数：7

共 69 条

[1] Sacks FM(1996)The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1001-1009
[2] Pfeffer MD(1998)Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1349-1357
[3] Moye LA(1994)Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 334 1383-1389
[4] Tonkin A(1995)Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1301-1307
[5] Aylward P(1996)The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1001-1009
[6] Colquhoun P(1996)Safety and tolerability of cholesterol lowering with Simvastatin during 5 years in the Scandinavian Simvastatin Survival Study Arch Intern Med 156 2085-2092
[7] Shepherd J(1998)Prevetnion of cardiovascular disease and death with pravastin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1349-1357
[8] Cobbe SM(1998)Primary Prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS JAMA 279 1615-1622
[9] Ford I(1990)Clinical experience with lovastatin Am J Cardiol 65 23F-26F
[10] Sacks FM(1998)An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor Arch Intern Med 158 577-584

← 1 2 3 4 5 6 7 →